Date: 22nd March 2019
Traditional methods of drug discover have started to evolve in recent times but the workflow from target identification through to the preclinical phase remains. The marriage of AI to drug discover, however, delivers a number of useful synergies and now Exscientia and Celgene have entered into a three-year AI drug discovery partnership, with the ambition of using AI to accelerate the discovery of small molecule therapeutic drug candidates. Combining the cutting-edge Centaur Chemist™ AI drug discovery platform from Exscientia together with Celgene’s areas of expertise in oncology and autoimmunity, the aim is to use AI to improve the speed of delivery for new treatments.
The company has also announced the establishment of a subsidiary, Exscientia K.K located in Osaka, Japan. Exscientia K.K is to spearhead its pharmaceutical interests in Japan, and throughout Asia.
Let’s hope we will be seeing novel, potent molecules emerging from Exscientia and Celgene in the not so distant future.
For more information please follow the link.